# A Study to Evaluate Safety, PK, Efficacy of TLC590 for Postsurgical Pain Management Following Bunionectomy

> **NCT03838133** · PHASE2 · COMPLETED · sponsor: **Taiwan Liposome Company** · enrollment: 150 (actual)

## Conditions studied

- Hallux Valgus

## Interventions

- **DRUG:** TLC590
- **DRUG:** Naropin®
- **DRUG:** Normal Saline
- **DRUG:** Bupivacaine

## Key facts

- **NCT ID:** NCT03838133
- **Lead sponsor:** Taiwan Liposome Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-03-05
- **Primary completion:** 2020-03-31
- **Final completion:** 2020-03-31
- **Target enrollment:** 150 (ACTUAL)
- **Last updated:** 2020-04-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03838133

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03838133, "A Study to Evaluate Safety, PK, Efficacy of TLC590 for Postsurgical Pain Management Following Bunionectomy". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT03838133. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*